Observational studyPituitary2016
Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Observational study in Pituitary, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.BMC endocrine disorders · 2021Pooled it
- Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.Endocrine · 2018Pooled it
- Prolactinomas treated with dopaminergic agonists: behavior in different moments of life.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2026Article
- Prolactinomas in women of reproductive age: a proposed reproductive-intent-based framework for diagnosis and management.Frontiers in endocrinology · 2026Review
- Impact of Tumor Size on Prolactinoma Characteristics and Treatment Outcomes: A Study of a Tunisian Cohort.Biomedicines · 2025Article
- Treatment of sexual dysfunction induced by hyperprolactinemia accompanied by reduced luteinizing hormone levels: A case report.Clinical case reports · 2024Article
- Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients.Neurosurgical review · 2023Article
- Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.Chinese neurosurgical journal · 2022Article
- Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas.Frontiers in endocrinology · 2022Article
- Treatment of hyperprolactinemia: A single-institute experience.Journal of the Chinese Medical Association : JCMA · 2021Article
- Giant Prolactinoma Presenting With Facial Nerve Palsy and Hemiparesis.Journal of the Endocrine Society · 2021Article
- High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?Endocrine · 2020Article
- Dopamine agonists in prolactinomas: when to withdraw?Pituitary · 2020Review
- Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.Hormones & cancer · 2019Article
- Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.Endocrine · 2018Article
- Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.Pituitary · 2018Article
- The Chance of Permanent Cure for Micro- and Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2018Article
- Article
- Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.Pituitary · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the study was to assess the effect of dopamine agonist (DA) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma.
methodsWe evaluated DA withdrawal in 67 patients with prolactinoma (50 female/17 male) who received DA treatment for at least 2 years and showed normalization of prolactin (PRL) levels and tumor disappearance or ≥50 % tumor shrinkage, retrospectively. Accordingly, patients were divided into two groups as remission and recurrence groups, and factors that predict recurrence were evaluated.
resultsThe overall remission rate was 46 %; the remission ratios were 65 % in microprolactinomas and 36 % in macroprolactinomas. Remission rates were 39 % in the bromocriptine withdrawal group and 55 % in the cabergoline withdrawal group. The maximum tumor diameter and baseline PRL levels were significantly higher in the recurrence group (p = 0.001 and p = 0.003, respectively). The mean duration of DA therapy was significantly longer in the remission group (88.7 ± 48.1 and 66.7 ± 30.4 months, respectively, p = 0.026).The mean time to recurrence was 5.3 ± 3.2 months. The mean PRL levels at recurrence time were significantly lower than baseline PRL levels (p = 0.001).
conclusionThe most important predictors of recurrence were maximum tumor diameter and baseline PRL levels in this study. The remission rate in our study group was higher, which was thought to be associated with the longer duration of DA treatment and that our patients were selected according to certain criteria. Despite these positive results, close monitoring is necessary for detection of early and late recurrence, especially within the first year after DA withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.